Get the Stockscreener App
21.55
1.35%
-0.31
Travere Therapeutics Inc stock is traded at $21.55, with a volume of 660.94K.
It is down -1.35% in the last 24 hours and up +13.03% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$21.86
Open:
$21.9
24h Volume:
660.94K
Relative Volume:
0.53
Market Cap:
$1.90B
Revenue:
$203.45M
Net Income/Loss:
$-351.45M
P/E Ratio:
-4.7363
EPS:
-4.55
Net Cash Flow:
$-369.41M
1W Performance:
+5.40%
1M Performance:
+13.03%
6M Performance:
+156.12%
1Y Performance:
+160.45%
1-Day Range:
$21.49
$22.25
1-Week Range:
$19.67
$22.25
52-Week Range:
$5.12
$22.25
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
21.57 | 1.90B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.53 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.11 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.70 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Travere therapeutics executive sells shares worth $106,081 - MSN
Travere Therapeutics (NASDAQ:TVTX) Sets New 12-Month HighHere's What Happened - MarketBeat
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shareholders Might Be Looking For Exit - Simply Wall St
Jennison Associates LLC Invests $14.22 Million in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Sandra Calvin Sells 3,348 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
Jula Inrig Sells 4,207 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
Focal Segmental Glomerulosclerosis Market Expected to rise, 2034 | Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara - Barchart
BlackRock, Inc. Increases Stake in Travere Therapeutics Inc - GuruFocus.com
Travere therapeutics CFO sells $104,463 in stock By Investing.com - Investing.com South Africa
Travere therapeutics SVP William Rote sells $177,050 in stock By Investing.com - Investing.com South Africa
Travere therapeutics CEO Eric Dube sells $1.02 million in stock By Investing.com - Investing.com South Africa
Quarterly Snapshot: Quick and Current Ratios for Travere Therapeutics Inc (TVTX) - The Dwinnex
Travere therapeutics' chief commercial officer sells $103,939 in stock By Investing.com - Investing.com South Africa
Focal Segmental Glomerulosclerosis Market Expected to rise, - openPR
Travere therapeutics executive sells shares worth $106,081 By Investing.com - Investing.com Canada
Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Sells 50,691 Shares of Stock - MarketBeat
Travere Therapeutics Stock: Executives Sell Amid Strategic Offering - sharewise
Travere therapeutics' chief commercial officer sells $103,939 in stock - Investing.com India
Travere therapeutics CEO Eric Dube sells $1.02 million in stock - Investing.com India
Travere therapeutics SVP William Rote sells $177,050 in stock - MSN
Travere therapeutics' SVP Elizabeth Reed sells $177,050 in stock - MSN
Calvin Sandra sells $67,361 in Travere Therapeutics shares By Investing.com - Investing.com Canada
Calvin Sandra sells $67,361 in Travere Therapeutics shares - Investing.com
Alport Syndrome Pipeline 2024: In-depth Clinical Trials - openPR
There is no way Travere Therapeutics Inc (TVTX) can keep these numbers up - SETE News
The Potential Rise in the Price of Travere Therapeutics Inc (TVTX) following insiders activity - Knox Daily
Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4.3%Should You Sell? - MarketBeat
Vanguard Group Inc Reduces Stake in Travere Therapeutics Inc - GuruFocus.com
(TVTX) Technical Data - Stock Traders Daily
Wedbush Research Analysts Raise Earnings Estimates for TVTX - MarketBeat
Wedbush Boosts Earnings Estimates for Travere Therapeutics - Defense World
What is Wedbush’s Estimate for TVTX FY2028 Earnings? - Defense World
Travere therapeutics CFO sells shares worth $16,383 - MSN
Travere therapeutics SVP William Rote sells $47,424 in stock - MSN
TVTX Stock Soars to 52-Week High, Reaching $20.36 - MSN
Travere therapeutics chief commercial officer sells $30,002 in stock - MSN
Travere therapeutics exec Elizabeth Reed sells common stock for $47,424 - MSN
Travere therapeutics director Roy Baynes sells $320,000 in stock - MSN
Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Christopher R. Cline Sells 865 Shares - MarketBeat
Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Sells 16,000 Shares of Stock - MarketBeat
Sandra Calvin Sells 925 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
Eric M. Dube Sells 10,736 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells $30,000.96 in Stock - MarketBeat
Travere therapeutics CEO Eric Dube sells shares for $208,922 - MSN
Travere Therapeutics (NASDAQ:TVTX) Sets New 1-Year HighWhat's Next? - MarketBeat
What is Wedbush's Estimate for TVTX FY2028 Earnings? - MarketBeat
TVTX Stock Soars to 52-Week High, Reaching $20.36 By Investing.com - Investing.com Australia
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Travere therapeutics CAO Calvin Sandra sells $17,520 in stock By Investing.com - Investing.com Canada
Travere therapeutics CFO sells shares worth $16,383 By Investing.com - Investing.com Australia
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Travere Therapeutics Inc Stock (TVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D |
Feb 03 '25 |
Sale |
19.78 |
8,951 |
177,051 |
95,719 |
| REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY |
Feb 03 '25 |
Sale |
19.78 |
8,951 |
177,051 |
89,482 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Feb 03 '25 |
Sale |
20.21 |
50,691 |
1,024,343 |
430,548 |
| Inrig Jula | CHIEF MEDICAL OFFICER |
Feb 03 '25 |
Sale |
20.12 |
4,207 |
84,645 |
85,236 |
| Inrig Jula | CHIEF MEDICAL OFFICER |
Feb 04 '25 |
Sale |
20.11 |
1,066 |
21,437 |
84,170 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER |
Feb 03 '25 |
Sale |
20.12 |
5,166 |
103,940 |
122,708 |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER |
Feb 03 '25 |
Sale |
20.12 |
5,192 |
104,463 |
90,038 |
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER |
Feb 03 '25 |
Sale |
20.12 |
3,348 |
67,362 |
63,654 |
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):